Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients

Ramanarayanan, Jeyanthi; Dunford, Lauren M.; Baer, Maria R.; Sait, Sheila N.J.; Lawrence, William; McCarthy, Philip L.

doi:10.1016/j.leukres.2005.10.015

« Previous Next »Leukemia Research
Volume 30, Issue 6 , Pages 701-705, June 2006

Chronic myeloid leukemia after treatment of lymphoid malignancies: Response to imatinib mesylate and favorable outcomes in three patients

Jeyanthi Ramanarayanan
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Lauren M. Dunford
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Maria R. Baer
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
Sheila N.J. Sait
- Clinical Cytogenetics Laboratory, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
William Lawrence
- Century Medical Group, Buffalo, NY, USA
Philip L. McCarthy
- Department of Medicine, Roswell Park Cancer Institute, State University of New York, Buffalo, NY, USA
- Corresponding author. Present address: Blood and Marrow Transplant Program, Roswell Park Cancer Institute, Elm and Carlton Streets, Buffalo, NY 14263, USA. Tel.: +1 716 845 1051; fax: +1 716 845 3272.

Received 3 September 2005; received in revised form 26 October 2005; accepted 29 October 2005. published online 07 March 2011.

Abstract

Recent improved treatments for lymphoid malignancies produce more long-term survivors, yet increase the risk for secondary malignancies. Therapy-related myelodysplasia and acute myeloid leukemia are well described, but secondary chronic myeloid leukemia (CML) has only rarely been reported. We report three patients with CML diagnosed 8, 10 and 2.5 years following Hodgkin's disease, non-Hodgkin's lymphoma and chronic lymphocytic leukemia therapy, respectively. BCR–ABL transcripts were not detected after completion of primary therapy in two cases. All three patients received imatinib therapy, with one patient subsequently undergoing allogeneic hematopoietic stem cell transplantation. All three patients have ongoing favorable responses to CML therapy.

Keywords: Chronic myeloid leukemia, Therapy-related leukemia, Chemo-radiotherapy, Autologous stem cell transplantation, Lymphoid malignancies